Yue Wyatt W
Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
J Inherit Metab Dis. 2016 Jul;39(4):489-98. doi: 10.1007/s10545-016-9923-3. Epub 2016 May 30.
At the SSIEM Symposium in Istanbul 2010, I presented an overview of protein structural approaches in the study of inborn errors of metabolism (Yue and Oppermann 2011). Five years on, the field is going strong with new protein structures, uncovered catalytic functions and novel chemical matters for metabolic enzymes, setting the stage for the next generation of drug discovery. This article aims to update on recent advances and lessons learnt on inborn errors of metabolism via the protein-centric approach, citing examples of work from my group, collaborators and co-workers that cover diverse pathways of transsulfuration, cobalamin and glycogen metabolism. Taking into consideration that many inborn errors of metabolism result in the loss of enzyme function, this presentation aims to outline three key principles that guide the design of small molecule therapy in this technically challenging field: (1) integrating structural, biochemical and cell-based data to evaluate the wide spectrum of mutation-driven enzyme defects in stability, catalysis and protein-protein interaction; (2) studying multi-domain proteins and multi-protein complexes as examples from nature, to learn how enzymes are activated by small molecules; (3) surveying different regions of the enzyme, away from its active site, that can be targeted for the design of allosteric activators and inhibitors.
在2010年于伊斯坦布尔举行的国际医学与生物工程科学院(SSIEM)研讨会上,我概述了蛋白质结构方法在先天性代谢缺陷研究中的应用(Yue和Oppermann,2011年)。五年过去了,该领域发展势头强劲,出现了新的蛋白质结构,发现了代谢酶的催化功能和新型化学物质,为下一代药物研发奠定了基础。本文旨在通过以蛋白质为中心的方法,介绍先天性代谢缺陷的最新进展和经验教训,并列举我所在团队、合作者及同事的工作实例,这些实例涵盖了转硫、钴胺素和糖原代谢等多种途径。鉴于许多先天性代谢缺陷会导致酶功能丧失,本报告旨在概述在这个技术挑战性领域中指导小分子疗法设计的三个关键原则:(1)整合结构、生化和基于细胞的数据,以评估突变驱动的酶在稳定性、催化作用和蛋白质-蛋白质相互作用方面的广泛缺陷;(2)以自然界中的多结构域蛋白质和多蛋白质复合物为例进行研究,了解酶是如何被小分子激活的;(3)研究酶远离其活性位点的不同区域,这些区域可作为变构激活剂和抑制剂设计的靶点。